ArticleNPJ precision oncology2022

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.

Yuki Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.